ALPN News and Press, Alpine Immune Sciences Inc. From 11/02/23

2023-11-02 13:15:49 ET More on etc. Dynatrace, Inc. (DT) Q2 2024 Earnings Call Transcript Geron Corporation 2023 Q3 - Results - Earnings Call Presentation Gates Industrial: Encouraging Q3 Report Needed To Finally Create A Floor For The Stock Icahn Enterprises...

2023-11-02 10:01:01 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...

-- Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy -- -- Higher dose povetacicept (240 mg) administered once every four weeks currently being explored -- ...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present new translational data for povetacicept and acazicolcept in systemic lupus erythem...

-- The Company will host an investor event following the presentation after the close of market on Thursday, November 2nd -- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune a...

2023-10-06 15:31:09 ET Summary Preliminary clinical data from the Alpine Immune Sciences, Inc. ongoing phase 3 RUBY-3 study will be presented at the American Society of Nephrology Annual Kidney Week Meeting in November 2023. The study focuses on autoimmune glomerulonephritis but i...

2023-10-04 08:58:48 ET Alpine Immune Sciences ( NASDAQ: ALPN ) has announced the appointment of Wolfgang Dummer to Chief Medical Officer effective October 2, 2023. He succeeds Andrew Sandler, who will transition responsibilities to Dummer through the r...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023. ...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company presented new preclinical data from a study of povetacicept in a murine experimental autoi...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will present new preclinical data from a study of povetacicept in a murine experimental au...